Literature DB >> 6420024

Cancer statistics, 1984.

E Silverberg.   

Abstract

Entities:  

Mesh：

Year:  1984        PMID： 6420024     DOI： 10.3322/canjclin.34.1.7

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN： 0007-9235            Impact factor:   508.702


× No keyword cloud information.
  22 in total

1.  Hormones and cancer.

Authors:  M E Blackstein
Journal:  Can Fam Physician       Date:  1984-06       Impact factor: 3.275

Review 2.  Wilms' tumor.

Authors:  R P Warrier; O Regueira
Journal:  Pediatr Nephrol       Date:  1992-07       Impact factor: 3.714

3.  Prevention in family practice: Consensus statement from the front line.

Authors:  G Satenstein; J Lemelin; C Folkerson; K A Scott; W E Hogg
Journal:  Can Fam Physician       Date:  1991-10       Impact factor: 3.275

4.  Predictive value of sputum cytology.

Authors:  J Benbassat; A Regev; P E Slater
Journal:  Thorax       Date:  1987-03       Impact factor: 9.139

5.  A method for the isolation and culture of human colonic crypts in collagen gels.

Authors:  R H Whitehead; A Brown; P S Bhathal
Journal:  In Vitro Cell Dev Biol       Date:  1987-06

6.  Process and outcome of care for patients with ovarian cancer.

Authors:  A Liberati; C Mangioni; L Bratina; G Carinelli; S Marsoni; F Parazzini; M Regallo; R Talamini; G Tognoni
Journal:  Br Med J (Clin Res Ed)       Date:  1985-10-12

7.  A randomized trial comparing mitoxantrone with doxorubicin in patients with stage IV breast cancer.

Authors:  J C Allegra; T Woodcock; S Woolf; I C Henderson; S Bryan; A Reisman; G Dukart
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

Review 8.  Patterns of metastasis and natural courses of breast carcinoma.

Authors:  Y T Lee
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

9.  Occult breast carcinoma in patients undergoing reduction mammaplasty.

Authors:  J R Gottlieb; P McKinney; M D Walkinshaw; R L Sperling
Journal:  Aesthetic Plast Surg       Date:  1989       Impact factor: 2.326

10.  Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma.

Authors:  P J Elson; L K Kvols; S E Vogl; D J Glover; R G Hahn; D L Trump; P P Carbone; J D Earle; T E Davis
Journal:  Invest New Drugs       Date:  1988-06       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.